Improvement in Human Tumour Oxygenation with Carbogen of Varying Carbon Dioxide Concentrations

Overview

Journal Radiother Oncol

Specialties Oncology
Radiology

Date 1999 Jun 15

PMID 10368040

Citations 14

Authors

M E Powell

D R Collingridge

M I Saunders

P J Hoskin

S A Hill

D J Chaplin

Affiliations

Soon will be listed here.

Abstract

Background And Purpose: Carbogen (95%O2, 5%CO2) is being used in clinical trials as a hypoxic radiosensitiser. Tolerance to carbogen can be a problem, this study compares tumour oxygenation during inhalation of hyperoxic gas containing either 2% or 5% CO2.

Materials And Methods: Tumour pO2 was measured in 16 patients using the Eppendorf pO2 histograph.

Results: After breathing gas containing either 5% or 2% CO2 an increase in median pO2 was measured in every tumour, the frequency of low pO2 values ( < or = 10 mmHg) fell from 47% to 29% in the 5% group and from 55% to 17% in the 2% group.

Conclusions: This study confirms that breathing 2% CO2 and 98% O2 is well tolerated and effective in increasing tumour oxygenation.

Citing Articles

The Role of Imaging Biomarkers to Guide Pharmacological Interventions Targeting Tumor Hypoxia.

Gallez B Front Pharmacol. 2022; 13:853568.

PMID: 35910347 PMC: 9335493. DOI: 10.3389/fphar.2022.853568.

How best to interpret measures of levels of oxygen in tissues to make them effective clinical tools for care of patients with cancer and other oxygen-dependent pathologies.

Swartz H, Flood A, Schaner P, Halpern H, Williams B, Pogue B Physiol Rep. 2020; 8(15):e14541.

PMID: 32786045 PMC: 7422807. DOI: 10.14814/phy2.14541.

Blood oxygenation level-dependent magnetic resonance imaging during carbogen breathing: differentiation between prostate cancer and benign prostate hyperplasia and correlation with vessel maturity.

Di N, Mao N, Cheng W, Pang H, Ren Y, Wang N Onco Targets Ther. 2016; 9:4143-50.

PMID: 27462169 PMC: 4939976. DOI: 10.2147/OTT.S105480.

Detecting gas-induced vasomotor changes via blood oxygenation level-dependent contrast in healthy breast parenchyma and breast carcinoma.

Wallace T, Patterson A, Abeyakoon O, Bedair R, Manavaki R, McLean M J Magn Reson Imaging. 2016; 44(2):335-45.

PMID: 26898173 PMC: 4949641. DOI: 10.1002/jmri.25177.

The Impact of Microenvironmental Heterogeneity on the Evolution of Drug Resistance in Cancer Cells.

Mumenthaler S, Foo J, Choi N, Heise N, Leder K, Agus D Cancer Inform. 2015; 14(Suppl 4):19-31.

PMID: 26244007 PMC: 4504404. DOI: 10.4137/CIN.S19338.